Lyell Immunopharma Inc Dossier
Qualitative Analysis
Business overview
Lyell Immunopharma, Inc. (NASDAQ: LYEL) is a clinical-stage cell therapy company dedicated to reprogramming T cells to achieve curative therapies for patients with solid tumors and hematologic malignancies. The company's proprietary technologies, including its Epi-R and genetic/epigenetic reprogramming platforms, address the primary barriers to successful adoptive T-cell therapy: T-cell exhaustion and loss of durable stemness. Lyell's lead clinical pipeline features rondecabtagene autoleucel (ronde-cel, formerly LYL314), an autologous dual-targeting CD19/CD20 CAR T-cell therapy in pivotal clinical development for large B-cell lymphoma (LBCL). Additionally, the company is advancing LYL273, a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in Phase 1 development for refractory metastatic colorectal cancer (mCRC).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing rondecabtagene autoleucel (ronde-cel), a next-generation dual-targeting CD19/CD20 CAR T-cell therapy, across two pivotal trials: the single-arm PiNACLE trial in 3L+ LBCL and the Phase 3 head-to-head PiNACLE-H2H trial comparing ronde-cel against standard-of-care CD19 CAR T-cell therapies in the 2L setting.
Expected impact: Aims to establish a best-in-class dual-targeting CAR T-cell therapy with superior complete response rates, longer duration of response, and a safer profile supporting outpatient administration.
Developing LYL273, an autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release, for metastatic colorectal cancer (mCRC) and other GCC-expressing solid tumors.
Expected impact: Expands the pipeline into solid tumors with a candidate that has demonstrated a 67% overall response rate in early clinical testing.
Focusing resources on late-stage CAR T-cell programs (ronde-cel and LYL273) while terminating earlier-stage programs, including LYL797 (ROR1-targeting CAR T) and LYL845 (TIL therapy), to optimize capital allocation.
Expected impact: Significantly reduces cash burn and extends the company's cash runway into the third quarter of 2027.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired to secure exclusive global rights to IMPT-314 (now rondecabtagene autoleucel or ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, shifting Lyell's strategic focus toward late-stage hematologic clinical programs.
Financial impact: Upfront consideration consisted of $30 million in cash and 37.5 million shares of Lyell common stock, plus contingent milestone payments and royalties.
Strategic Partnerships
Provides Lyell with exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize LYL273, a promising GCC-targeted CAR T-cell therapy for metastatic colorectal cancer.
Terms: $40 million upfront cash payment, 1.9 million shares of common stock, and up to $820 million in potential clinical, regulatory, and commercial milestones, plus tiered royalties up to 10%.
Collaborating on cytokine regulation technologies, specifically utilizing engineered IL-12 (trIL-12) to enhance T-cell survival and functionality in the solid tumor microenvironment.
Terms: Not fully disclosed.